SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,858.70+0.21%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%
Benzinga
Updated: Oct 10, 2026

Daniel Brims's Stock Ratings

Lake Street Analyst

Daniel Brims is an analyst at Lake Street. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends.

Overall Average Return

-6.02%

Smart Score

31.4%

Overall Average Return Percentile

25th

Number of Ratings

7
Buy NowGet Alert
10/06/2026RZLTBuy Now
Rezolute
$4.90144.9%$9 → $12MaintainsBuyGet Alert
09/30/2026RZLTBuy Now
Rezolute
$4.9083.67% → $9Initiates → BuyGet Alert
09/17/2026SPRBBuy Now
Spruce Biosciences
$44.02238.48% → $149Initiates → BuyGet Alert
09/17/2026KYNBBuy Now
Kyntra Bio
$6.11571.03% → $41Initiates → BuyGet Alert
05/28/2026VKTXBuy Now
Viking Therapeutics
$28.60211.19% → $89Initiates → BuyGet Alert
05/28/2026ALGSBuy Now
Aligos Therapeutics
$5.45725.69% → $45Initiates → BuyGet Alert
04/14/2026KURABuy Now
Kura Oncology
$10.60116.98% → $23Initiates → BuyGet Alert

Recent Analyst Stock Rating News

Kura Oncology Q2 2026 Earnings Call Transcript
Kura Oncology Q2 2026 Earnings Call Transcript
On Wednesday, Kura Oncology (NASDAQ:KURA) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript
Kura Oncology (NASDAQ:KURA) released first-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data
Cantor Still Expects Threshold Pharma To More Than Triple, Says 2016 Will Be 'Data Rich' Year
Cantor Still Expects Threshold Pharma To More Than Triple, Says 2016 Will Be 'Data Rich' Year
Cantor Sees Possible Acquisitions For Valeant Pharmaceuticals In 2015
Cantor Sees Possible Acquisitions For Valeant Pharmaceuticals In 2015
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved